Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
NO more than a few hundred US children have a rare disease characterised by ultra-high levels of bad cholesterol. Yet, to the giant drugmaker AstraZeneca, this small group could be worth billions of dollars.
The company is making a bold attempt to fend off impending